Olema Pharmaceuticals (OLMA) Insider Trading & Ownership $8.28 -0.44 (-5.05%) (As of 11/20/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Olema Pharmaceuticals (NASDAQ:OLMA) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage19.40%Number OfInsiders Buying(Last 12 Months)2Amount OfInsider Buying(Last 12 Months)$3.03 MNumber OfInsiders Selling(Last 12 Months)4Amount OfInsider Selling(Last 12 Months)$38.28 M Get OLMA Insider Trade Alerts Want to know when executives and insiders are buying or selling Olema Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address OLMA Insider Buying and Selling by Quarter Ad Priority GoldJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. Olema Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails8/1/2024Biocapital Advisors L ParadigmMajor ShareholderSell2,400,000$14.91$35,784,000.00 7/29/2024Cyrus HarmonDirectorSell4,066$15.58$63,348.28 7/11/2024Cyrus HarmonDirectorSell5,000$12.26$61,300.00 6/28/2024Cyrus HarmonDirectorSell20,000$10.77$215,400.00 6/3/2024Cyrus HarmonDirectorSell5,000$10.93$54,650.00 5/31/2024Cyrus HarmonDirectorSell15,000$9.41$141,150.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 5/6/2024Cyrus HarmonDirectorSell5,000$10.92$54,600.00 4/30/2024Cyrus HarmonDirectorSell15,000$9.51$142,650.00 3/28/2024Cyrus HarmonDirectorSell20,000$10.97$219,400.00 2/29/2024Cyrus HarmonDirectorSell25,000$12.41$310,250.00 1/31/2024Cyrus HarmonDirectorSell25,000$12.23$305,750.00 12/6/2023Biocapital Advisors L ParadigmMajor ShareholderBuy100,000$11.60$1,160,000.00 12/5/2023G. Walmsley GrahamDirectorBuy131,870$14.19$1,871,235.30 11/30/2023Cyrus HarmonDirectorSell25,000$12.57$314,250.00 11/21/2023Cyrus HarmonDirectorSell4,192$14.86$62,293.12 11/21/2023Naseem ZojwallaInsiderSell7,461$14.84$110,721.24 11/21/2023Sean BohenCEOSell29,293$14.88$435,879.84 (Data available from 1/1/2013 forward) OLMA Insider Trading Activity - Frequently Asked Questions Who is on Olema Pharmaceuticals's Insider Roster? The list of insiders at Olema Pharmaceuticals includes Biocapital Advisors L Paradigm, Bvf Partners L P/Il, Cyrus Harmon, David C Myles, G. Walmsley Graham, Kinney Horn, Naseem Zojwalla, and Sean Bohen. Learn more on insiders at OLMA. What percentage of Olema Pharmaceuticals stock is owned by insiders? 19.40% of Olema Pharmaceuticals stock is owned by insiders. Learn more on OLMA's insider holdings. Which Olema Pharmaceuticals insiders have been buying company stock? The following insiders have purchased OLMA shares in the last 24 months: Biocapital Advisors L Paradigm ($1,160,000.00), Bvf Partners L P/Il ($14,818,370.88), and G. Walmsley Graham ($1,871,235.30). How much insider buying is happening at Olema Pharmaceuticals? Insiders have purchased a total of 1,737,802 OLMA shares in the last 24 months for a total of $17,849,606.18 bought. Which Olema Pharmaceuticals insiders have been selling company stock? The following insiders have sold OLMA shares in the last 24 months: Biocapital Advisors L Paradigm ($35,784,000.00), Cyrus Harmon ($2,984,541.40), David C Myles ($366,548.27), Naseem Zojwalla ($110,721.24), and Sean Bohen ($435,879.84). How much insider selling is happening at Olema Pharmaceuticals? Insiders have sold a total of 2,727,421 Olema Pharmaceuticals shares in the last 24 months for a total of $39,681,690.75 sold. Olema Pharmaceuticals Key ExecutivesDr. Sean P. Bohen M.D. (Age 57)Ph.D., President, CEO & Director Compensation: $1.15MMr. Shane William Charles Kovacs M.B.A. (Age 50)Chief Operating & Financial Officer Compensation: $820.37kDr. Naseem Zojwalla M.D. (Age 51)Chief Medical Officer Compensation: $753.37kMs. Julie DexterSenior VP & Head of PeopleDr. David C. Myles Ph.D. (Age 61)Chief Discovery & Non-Clinical Development Officer Compensation: $200kMs. Demiana Faltaos Ph.D.Pharm.D., VP & Head of Clinical PharmacologyMr. John B. Moriarty Jr. (Age 56)ESQ., J.D., Corporate Secretary Compensation: $434.32kMs. Sasha Austin CPAVP of Finance & Controller More Insider Trading Tools from MarketBeat Related Companies SUPN Insider Selling CNTA Insider Selling MNKD Insider Selling GPCR Insider Selling HRMY Insider Selling IRON Insider Selling XNCR Insider Selling NRIX Insider Selling DVAX Insider Selling ARVN Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Selling Into 3 Rallies: Investors Should Do the OppositeInsiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking On This page (NASDAQ:OLMA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Olema Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Olema Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.